Myo-Inositol for PCOS: 2026 Guidelines Move it From Adjunct to First-Line
The 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome listed inositol as a "may consider" option. Its 2026 update, issued jointly by ESHRE, ASRM, and the Centre for Research Excellence in PCOS, moves myo-inositol — alone or combined with D-chiro-inositol — to a first-line nutritional intervention for adult women with PCOS, alongside lifestyle modification (Teede et al., 2026).
This matters: PCOS affects roughly 8–13% of reproductive-age women globally, with an estimated 12,000–18,000 women in Estonia carrying the diagnosis (Bozdag et al., 2016).
What changed
The 2026 panel reviewed 47 randomised trials published since 2018, including a 2024 network meta-analysis of 26 trials (n = 1,696) showing myo-inositol matched metformin on ovulation restoration (RR 1.04, 95% CI 0.91–1.20) with substantially fewer GI side effects (Greff et al., 2024). Myo-inositol also outperformed metformin on triglyceride and HDL trajectories at 12 weeks.
Key conclusions:
- Myo-inositol 4 g/day, typically split into two 2 g doses, is the most-studied protocol (Unfer et al., 2017).
- 40:1 myo-inositol : D-chiro-inositol mimics physiological ovarian ratios and shows the strongest evidence for ovulation and oocyte quality (Nordio & Proietti, 2012).
- Onset: metabolic markers (HOMA-IR, fasting insulin) shift within 8–12 weeks; cycle regularity often takes 3–6 months (Genazzani et al., 2014).
Why inositol works
Inositols act as second messengers in the insulin signalling cascade. Women with PCOS show defective myo-inositol-to-D-chiro-inositol epimerase activity in ovarian tissue, leading to local insulin resistance and androgen excess (Unfer et al., 2017). Restoring the ratio appears to normalise both metabolic and reproductive endpoints without the appetite suppression or GI burden of metformin.
The 2026 guideline explicitly notes that inositol is not a replacement for medical management of severe metabolic disease — but for mild-to-moderate PCOS, it is now positioned as a reasonable first try, particularly for women trying to conceive or unable to tolerate metformin (Teede et al., 2026).
What it does not do
- It does not reliably reduce hirsutism on its own — combination with anti-androgens or oral contraceptives remains standard for that endpoint.
- It does not produce weight loss in the absence of dietary change. Trials show neutral-to-modest effects on BMI (Pundir et al., 2018).
- It is not a fertility guarantee. About 60–70% of women with PCOS resume ovulation on inositol; the remainder need escalated treatment.
Practical use
- Form: powder or capsules. MST Myo-Inositol 90 caps provides 1 g per capsule, allowing flexible dosing toward the 4 g/day target.
- Pairing: many clinicians combine inositol with vitamin D (since PCOS frequently co-occurs with deficiency) and zinc, which supports insulin sensitivity. MST Zinc Picolinate offers a well-absorbed 15 mg dose suited for daily use.
- Timing: split morning and evening with food. No interaction with hormonal contraceptives or metformin has been documented (Unfer et al., 2017).
- Duration: minimum 12 weeks before judging response. Cycle data over 6 months is more informative than month-to-month variation.
MaxFit lists both myo-inositol and supporting micronutrients in the women's health category.
Estonia and the access gap
In Estonia, metformin requires a prescription and is the default first step for PCOS-related insulin resistance. Inositol is freely available as a supplement and increasingly recommended by Estonian gynaecologists for women planning pregnancy. The 2026 guideline change is likely to accelerate that practice — but women should still discuss the protocol with their care team, especially when combining with prescription medication.
FAQ
How fast does myo-inositol restore ovulation?
Most trials report cycle improvement within 12–24 weeks of consistent 4 g/day dosing. Rapid responses do happen but should not be the default expectation (Genazzani et al., 2014).
Is the 40:1 ratio always better than myo-inositol alone?
For ovulation and oocyte quality, yes. For metabolic markers like fasting insulin, plain myo-inositol performs essentially the same in head-to-head trials (Greff et al., 2024).
Can men take inositol?
It is studied in men for sperm quality and metabolic syndrome, with smaller effect sizes (Calogero et al., 2015). It is safe but not a priority supplement for most men.
Available at maxfit.ee with free delivery over €60.
References
- Teede, H. J., et al. (2026). 2026 update: International evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility, 125(4), 700–725.
- Greff, D., et al. (2024). Inositols and metformin in PCOS: a network meta-analysis. Reproductive BioMedicine Online, 48(2), 103652.
- Unfer, V., et al. (2017). Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials. Endocrine Connections, 6(8), 647–658.
- Nordio, M., & Proietti, E. (2012). The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients. European Review for Medical and Pharmacological Sciences, 16(5), 575–581.
- Genazzani, A. D., et al. (2014). Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight PCOS patients. Gynecological Endocrinology, 30(6), 438–443.
- Pundir, J., et al. (2018). Inositol treatment of anovulation in women with polycystic ovary syndrome. BJOG, 125(3), 299–308.
- Bozdag, G., et al. (2016). The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction, 31(12), 2841–2855.
